Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bristol-Myers Squibb Co BMY

Healthcare
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule... see more

Recent & Breaking News (NYSE:BMY)

Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of Care (docetaxel) for Previously-Treated Squamous Non-Small Cell Lung Cancer in Phase III Trial

Business Wire May 31, 2015

Phase III CheckMate -067 Trial Demonstrates Superior Progression-Free Survival of Opdivo+Yervoy Regimen or Opdivo Monotherapy vs. Yervoy Monotherapy in Previously Untreated Patients with Advanced Melanoma

Business Wire May 31, 2015

Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers Squibb's PD-1 Immune Checkpoint Inhibitor is First to Demonstrate Anti-Tumor Activity In Patients With Hepatocellular Carcinoma

Business Wire May 29, 2015

Opdivo (nivolumab) First PD-1 Inhibitor to Demonstrate Superior Overall Survival Versus Standard of Care (docetaxel) in Previously-Treated Non-Squamous Non-Small Cell Lung Cancer in Pivotal Phase III Trial

Business Wire May 29, 2015

Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights

Business Wire May 28, 2015

Bristol-Myers Squibb Announces the Expiration of its Cash Tender Offer

Business Wire May 27, 2015

Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Nivolumab (Opdivo, Nivolumab BMS) for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer in Previously-Treated Patients

Business Wire May 22, 2015

Bristol-Myers Squibb Receives Amended U.S. FDA Breakthrough Therapy Designation for Investigational Daclatasvir-based Hepatitis C Regimen

Business Wire May 20, 2015

Eric Stonestreet, of Television's Hit Comedy, "Modern Family" Joins Forces with Bristol-Myers Squibb to Launch Ready. Raise. Rise.(TM) to Honor Those Affected by Cancer and Increase Awareness of Innovative Immuno-Oncology Research

Business Wire May 19, 2015

Bristol-Myers Squibb to Present Data at 2015 American Society of Clinical Oncology (ASCO) Annual Meeting that Demonstrate the Promise of its Broad Immuno-Oncology Portfolio Across Solid Tumors and Blood Cancers Including Multiple Myeloma

Business Wire May 13, 2015

Bristol-Myers Squibb Announces the Pricing Terms of its Cash Tender Offer For Up to $500 Million Aggregate Principal Amount of its Outstanding Debt Securities

Business Wire May 12, 2015

Bristol-Myers Squibb Announces the Early Results of its Cash Tender Offer For Up to $400 Million Aggregate Principal Amount of its Outstanding Debt Securities; Increases the Maximum Amount of the Tender Offer

Business Wire May 12, 2015

Long-Term, 7-Year Study of Nulojix® (belatacept) Regimen Demonstrates Statistically Significant Relative Risk Reduction of Death or Graft Loss over Cyclosporine Regimen in Kidney Transplant

Business Wire May 6, 2015

Bristol-Myers Squibb to Present at Bank of America Merrill Lynch 2015 Health Care Conference

Business Wire May 4, 2015

Bristol-Myers Squibb Prices Euro1.15 Billion of Senior Notes

Business Wire April 29, 2015

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Previously Untreated Advanced Melanoma

Business Wire April 29, 2015

Bristol-Myers Squibb to Take Part in Deutsche Bank Global Health Care Conference

Business Wire April 29, 2015

Hepatitis C cure rate of 94% achieved in patients post-liver transplant and up to 94% in those with advanced cirrhosis (Child-Pugh Class A and B) following 12-week, oral treatment with combination daclatasvir and sofosbuvir once daily, plus ribavirin, in ALLY-1 trial

Canada NewsWire April 29, 2015

Bristol-Myers Squibb Announces Cash Tender Offer For Up to $400 Million Aggregate Principal Amount of its Outstanding Debt Securities

Business Wire April 28, 2015

Bristol-Myers Squibb Reports First Quarter Financial Results

Business Wire April 28, 2015